Enanta Pharmaceuticals (ENTA) Other Non Operating Income (2012 - 2022)
Enanta Pharmaceuticals posted quarterly Other Non Operating Income of $393000.0 for Q2 2022, down 10.48% year-on-year from $439000.0 in Q2 2021, and up 54.12% on a QoQ basis from $255000.0 in Q1 2022.
Enanta Pharmaceuticals (ENTA) has 11 years of Other Non Operating Income data on file, last reported at $393000.0 in Q2 2022.
- For the quarter ending Q2 2022, Other Non Operating Income fell 10.48% year-over-year to $393000.0; the trailing twelve-month figure through Jun 2022 stood at -$782000.0 (up 78.64% YoY), and the FY2021 full-year result was -$27000.0, down 118.12% from the prior year.
- Other Non Operating Income for Q2 2022 stood at $393000.0, up from $255000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $2.4 million in Q2 2019 and bottomed at -$5.3 million in Q3 2020.
- The 5-year median for Other Non Operating Income is $393000.0 (2022), against an average of $222800.0.
- The widest annual swing landed in 2018, when Other Non Operating Income slumped 115.15%; it then surged 24050.0% in 2019.
- A 5-year view of Other Non Operating Income shows it stood at -$100000.0 in 2018, then soared by 2176.0% to $2.1 million in 2019, then slumped by 67.39% to $677000.0 in 2020, then sank by 61.89% to $258000.0 in 2021, then jumped by 52.33% to $393000.0 in 2022.
- The last three Other Non Operating Income figures came in at $393000.0 (Q2 2022), $255000.0 (Q1 2022), and $258000.0 (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 393,000.00 |
| Mar 31, 2022 | 255,000.00 |
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | -1.69 Mn |
| Jun 30, 2021 | 439,000.00 |
| Mar 31, 2021 | 545,000.00 |
| Dec 31, 2020 | 677,000.00 |
| Sep 30, 2020 | -5.32 Mn |
| Jun 30, 2020 | 1.45 Mn |
| Mar 31, 2020 | 1.95 Mn |
| Dec 31, 2019 | 2.08 Mn |
| Jun 30, 2019 | 2.42 Mn |
| Sep 30, 2018 | -100,000.00 |
| Jun 30, 2018 | 10,000.00 |
| Mar 31, 2018 | -11,000.00 |
| Dec 31, 2017 | 41,000.00 |
| Sep 30, 2017 | 660,000.00 |
| Jun 30, 2017 | -17,000.00 |
| Mar 31, 2017 | -15,000.00 |
| Dec 31, 2016 | -13,000.00 |
| Sep 30, 2016 | 471,000.00 |
| Jun 30, 2016 | 447,000.00 |
| Mar 31, 2016 | 472,000.00 |
| Dec 31, 2015 | 329,000.00 |
| Sep 30, 2015 | 509,000.00 |
| Jun 30, 2015 | 287,000.00 |
| Mar 31, 2015 | 210,000.00 |
| Dec 31, 2014 | 301,000.00 |
| Sep 30, 2014 | 236,000.00 |
| Jun 30, 2014 | 36,000.00 |
| Mar 31, 2014 | -76,000.00 |
| Dec 31, 2013 | 87,000.00 |
| Sep 30, 2013 | 258,000.00 |
| Jun 30, 2013 | 40,000.00 |
| Mar 31, 2013 | 252,000.00 |
| Dec 31, 2012 | 48,000.00 |
| Sep 30, 2012 | 44,000.00 |
| Jun 30, 2012 | 27,000.00 |
| Mar 31, 2012 | 16,000.00 |